Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05969951
Other study ID # ShengjingH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 14, 2021
Est. completion date April 2026

Study information

Verified date April 2023
Source Shengjing Hospital
Contact Chuming Zhou, master
Phone +8602496615-21111
Email zcm_06@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Venous thromboembolism (VTE) is one of the most common complications in perioperative period and the most common cause of postoperative death. VTE includes deep vein thrombosis (DVT) and acute pulmonary thromboembolism (PTE). Since the embolus of PTE comes from the deep vein thrombosis, and not all PE patients can present obvious clinical symptoms, VTE is currently considered as a disease for research, prevention, diagnosis and treatment at home and abroad. Therefore, we urgently need to develop a more comprehensive and reliable perioperative VTE risk prevention system based on medical big data and multi-module computer in current clinical practice, so as to effectively guide the prevention of DVT/PE, and thus reduce the perioperative mortality.


Description:

Venous thromboembolism (VTE) is one of the most common complications in perioperative period and the most common cause of postoperative death. VTE includes deep vein thrombosis (DVT) and acute pulmonary thromboembolism (PTE). Since the embolus of PTE comes from the deep vein thrombosis, and not all PE patients can present obvious clinical symptoms, VTE is currently considered as a disease for research, prevention, diagnosis and treatment at home and abroad. Therefore, we urgently need to develop a more comprehensive and reliable perioperative VTE risk prevention system based on medical big data and multi-module computer in current clinical practice, so as to effectively guide the prevention of DVT/PE, and thus reduce the perioperative mortality. As early as 1991, Caprini et al. collated and published the clinical scale of VTE risk assessment based on the study data of 538 patients. In 2010, Caprini et al. conducted retrospective verification of this scale again among 8216 patients, thus making this scale an important reference for many medical institutions to assess the risk of VTE occurrence in perioperative patients, and it has been used ever since. However, over the past 30 years, the disease spectrum, surgical methods, anesthesia methods and the cognition of thrombus formation susceptibility of surgical patients have all undergone great changes. Perioperative patients who are evaluated by Caprini scale and take preventive measures according to its suggested measures will still have postoperative VTE. Therefore, in recent years, scholars have published new VTE risk prediction methods, such as Kucher model, Padua model and so on. However, the study cases established by the model are almost only about 1000 cases, and the included research indicators are limited. The new technology realizes for the first time the identification, reading and integration of VTE-related risk indicators under the guidance of informatization and digitalization, providing technical support for big data analysis; To realize forward-looking, big data, multi-variable, multi-module VTE-related risk assessment and prediction; The existing scoring system should be improved to provide a more reliable and operable scoring model for perioperative VTE prevention and treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 100000
Est. completion date April 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 10 Years to 90 Years
Eligibility Inclusion Criteria: 1. perioperative patients; 2. Age range from 10 to 90 years old, gender unlimited; 3. Sign informed consent. Exclusion Criteria: - (1) non-operative patients; (2) have developed deep vein thrombosis and/or pulmonary embolism before surgery; (3) emergency operation patients; (4) Patients considered unsuitable for inclusion in the study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Shengjing Hospital of China Medical University Shenyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Shengjing Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Cronin M, Dengler N, Krauss ES, Segal A, Wei N, Daly M, Mota F, Caprini JA. Completion of the Updated Caprini Risk Assessment Model (2013 Version). Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619838052. doi: 10.1177/1076029619838052. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary DVT incidence rate Incidence of perioperative deep venous thromboembolism 7±2days after operation
Primary PE incidence rate Incidence of perioperative acute pulmonary thromboembolism 7±2days after operation
See also
  Status Clinical Trial Phase
Recruiting NCT05040906 - A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients Phase 3
Completed NCT01894971 - The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube Phase 3
Recruiting NCT05376111 - Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients Phase 2